Description of Syros Pharmaceuticals Inc's Business Segments

Syros Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies aimed at treating cancer and other diseases with significant unmet medical needs. The company employs a platform-based approach to drug discovery and development, which leverages its expertise in gene control to create therapies that target specific pathways involved in disease progression.

Segments

1. Oncology
- Description: The primary focus of Syros Pharmaceuticals is on the oncology segment, where the company is dedicated to developing targeted therapies for various forms of cancer. This segment includes therapies designed to modulate gene expression in cancer cells, with the goal of improving treatment outcomes for patients.
- Target Indications: The company is actively pursuing treatments for hematologic malignancies such as acute myeloid leukemia (AML) and other solid tumors.

Products

1. SY-1425 (Tamibarotene)
- Description: A selective retinoic acid receptor alpha (RARA) agonist currently being studied for the treatment of patients with acute myeloid leukemia. It has shown promise in patients with RARA-positive AML and is being evaluated in clinical trials. This product aims to modulate gene expression in a way that induces differentiation and improves survival rates.

2. SY-5609
- Description: A selective cyclin-dependent kinase 7 (CDK7) inhibitor. This drug is designed to halt cancer cell proliferation and has applications in various cancer types. Syros is investigating SY-5609 in early-stage clinical trials for patients with solid tumors, particularly focusing on its safety and efficacy.

3. SY-2101
- Description: An investigational therapy aimed at treating acute myeloid leukemia by targeting the underlying genetic mechanisms of the disease. It specifically targets patients with certain mutations that make them susceptible to this therapy. This product represents an advancement in precision medicine by focusing on specific genetic profiles.

Services

1. Research and Development (R&D)
- Description: Syros Pharmaceuticals invests significantly in R&D to discover and develop new therapeutics. Its R&D efforts are focused on understanding the biology of diseases and applying gene control technology to create novel treatments. Through collaborations and partnerships, Syros aims to enhance its discovery process and clinical trial outcomes.

2. Clinical Trials
- Description: The company conducts various clinical trials to evaluate the safety and efficacy of its product candidates. This includes Phase 1 and Phase 2 studies aimed at understanding dosage, effectiveness, and patient responses. Syros often collaborates with academic institutions and clinical research organizations to advance its trials.

3. Strategic Partnerships
- Description: Syros seeks strategic partnerships with other biotech and pharmaceutical companies, academic institutions, and research organizations to broaden its capabilities and access to markets. These collaborations may involve co-development agreements, research collaborations, or licensing agreements.

Focus Areas

- Gene Control Platform: Syros employs its gene control platform to discover and optimize drugs that specifically target gene pathways involved in cancer. This platform is fundamental to the companys ability to innovate and create effective treatments.

- Precision Medicine: The company emphasizes a precision medicine approach by targeting specific patient populations based on genetic profiling and biomarkers. This strategy aims to provide more effective and personalized treatment options.

- Hematologic Malignancies and Solid Tumors: Syross pipeline is focused primarily on hematologic malignancies, such as acute myeloid leukemia, as well as certain solid tumors. The companys ongoing research is dedicated to identifying new therapeutic options for these challenging conditions.

Through its focused product pipeline and dedication to innovative research methodologies, Syros Pharmaceuticals Inc. aims to create significant advancements in biopharmaceutical therapies for cancer and other severe diseases.

Annual Report on Syros Pharmaceuticals Inc Divisions, Sales by Country

Twelve months ended 2023
SYRS s Annual Revenue by Geography and Business Segments	Sales (in millions $)	% (of total Sales)
Total	9.94	100 %

Twelve months ended 2023
SYRS s Annual Income by Country and Business Segments	Income (in millions $)	% (Profit Margin)
Total	-164.57	-

Twelve months ended 2023
Annual Revenue and Income Growth by Country and Business Segments	% Y/Y Sales Growth	% Y/Y Income Growth

Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com